Fulgent Genetics (NASDAQ:FLGT) Updates FY 2026 Earnings Guidance

Fulgent Genetics (NASDAQ:FLGT) updated its FY 2026 earnings guidance on Friday. The company provided earnings per share guidance of -1.450–1.450 for the period, compared to the consensus earnings per share estimate of -0.590. The company issued revenue guidance of $350.0 million-$350.0 million, compared to the consensus revenue estimate of $343.6 million.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on FLGT shares. Raymond James Financial restated an “outperform” rating and set a $36.00 price objective on shares of Fulgent Genetics in a research report on Friday, November 14th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Fulgent Genetics in a report on Thursday, January 22nd. Piper Sandler raised their target price on Fulgent Genetics from $21.00 to $30.00 and gave the company a “neutral” rating in a report on Tuesday, November 11th. Zacks Research downgraded shares of Fulgent Genetics from a “strong-buy” rating to a “hold” rating in a research report on Monday, February 9th. Finally, Wall Street Zen lowered shares of Fulgent Genetics from a “buy” rating to a “hold” rating in a research report on Saturday, December 13th. Two research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $32.00.

Fulgent Genetics Stock Performance

Shares of Fulgent Genetics stock traded down $9.43 during trading on Friday, hitting $15.33. The company’s stock had a trading volume of 2,379,715 shares, compared to its average volume of 270,850. The company has a market capitalization of $473.85 million, a PE ratio of -11.03 and a beta of 0.86. Fulgent Genetics has a 52 week low of $14.57 and a 52 week high of $31.04. The company has a fifty day simple moving average of $25.91 and a two-hundred day simple moving average of $24.87.

Insider Buying and Selling

In other Fulgent Genetics news, insider Hanlin Gao sold 1,075 shares of Fulgent Genetics stock in a transaction on Tuesday, December 2nd. The shares were sold at an average price of $28.33, for a total value of $30,454.75. Following the transaction, the insider directly owned 952,890 shares of the company’s stock, valued at approximately $26,995,373.70. The trade was a 0.11% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Jian Xie sold 1,140 shares of the stock in a transaction dated Tuesday, December 2nd. The shares were sold at an average price of $28.33, for a total value of $32,296.20. Following the completion of the sale, the chief operating officer owned 336,749 shares of the company’s stock, valued at approximately $9,540,099.17. This trade represents a 0.34% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 31.76% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Fulgent Genetics

Several hedge funds have recently added to or reduced their stakes in the stock. Kestra Advisory Services LLC bought a new position in shares of Fulgent Genetics in the 4th quarter worth about $35,000. Raymond James Financial Inc. bought a new stake in shares of Fulgent Genetics during the second quarter valued at approximately $49,000. Quantbot Technologies LP bought a new stake in shares of Fulgent Genetics during the 3rd quarter worth about $61,000. Los Angeles Capital Management LLC bought a new stake in Fulgent Genetics during the fourth quarter worth approximately $218,000. Finally, Advisors Asset Management Inc. boosted its stake in Fulgent Genetics by 2,205.7% during the fourth quarter. Advisors Asset Management Inc. now owns 8,485 shares of the company’s stock valued at $223,000 after buying an additional 8,117 shares in the last quarter. 48.06% of the stock is currently owned by hedge funds and other institutional investors.

Fulgent Genetics Company Profile

Fulgent Genetics, Inc (NASDAQ: FLGT) is a California-based company specializing in high-complexity genetic testing and diagnostic services. Operating from its headquarters in Temple City, Fulgent leverages next-generation sequencing (NGS) technologies and advanced bioinformatics to deliver a broad range of clinical and research assays. The company’s infrastructure includes CAP- and CLIA-certified laboratories, enabling it to process large volumes of samples with rapid turnaround times.

Fulgent’s product portfolio encompasses hereditary cancer panels, rare disease and neuromuscular disorder testing, pharmacogenomic screenings, non-invasive prenatal tests, and infectious disease assays including COVID-19 diagnostics.